Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

NCT02983006 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: DS-8273a
BIOLOGICAL: Nivolumab

Sponsor

NYU Langone Health

Collaborators

[object Object]
[object Object]